ReviewCurrent opinion in pharmacology2012
Drug induced rhabdomyolysis.
Review in Current opinion in pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 171 citations in OpenAlex.
- Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice.Critical care (London, England) · 2016Pooled it
- Oxaliplatin-induced rhabdomyolysis in a postoperative rectal cancer patient: a case report and literature review.Frontiers in pharmacology · 2026Review
- Rhabdomyolysis Following Trimethoprim-Sulfamethoxazole Therapy: A Case Report and Review of the Literature.Current drug safety · 2026Review
- Predicting Acute Kidney Injury in Acute Rhabdomyolysis.Journal of clinical medicine · 2025Article
- Article
- HyperCKemia and rhabdomyolysis following lacosamide initiation: two case reports.Journal of neurology · 2025Article
- A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases.BMC psychiatry · 2025Article
- Oxcarbazepine Induced Rhabdomyolysis and Acute Kidney Injury: A Case Report.Case reports in nephrology · 2025Article
- Use of Hemoadsorption and Continuous Venovenous Hemodialysis With Enhanced Middle Molecule Clearance in Drug-Induced Rhabdomyolysis.Case reports in critical care · 2025Article
- Gabapentinoids-Induced Rhabdomyolysis/Myopathy: Clinical Characteristics, Management, Outcomes, and Critical Safety Alerts.Journal of pain research · 2025Review
- Past, present, and future biomarkers of kidney function and injury: The relationship with antibiotics.International journal of antimicrobial agents · 2024Review
- Statin-Induced Autoimmune Myopathy: A Diagnostic Challenge in Muscle Weakness.The American journal of case reports · 2024Article
- Rhabdomyolysis Risk: The Dangers of Tribulus Terrestris, an Over-the-Counter Supplement.The American journal of case reports · 2024Article
- Review
- Advancing Adverse Drug Reaction Prediction with Deep Chemical Language Model for Drug Safety Evaluation.International journal of molecular sciences · 2024Article
- A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases.Frontiers in pharmacology · 2024Article
- Case report: two cases of rhabdomyolysis following esketamine treatment.Frontiers in psychiatry · 2024Article
- Rhabdomyolysis or Severe Acute Hepatitis Associated with the Use of Red Yeast Rice Extracts: an Update from the Adverse Event Reporting Systems.Current atherosclerosis reports · 2023Review
- Article
- Urinary exosomes: a promising biomarker of drug-induced nephrotoxicity.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Rhabdomyolysis is a clinical condition of potential life threatening destruction of skeletal muscle caused by diverse mechanisms including drugs and toxins. Given the fact that structurally not related compounds cause an identical phenotype pinpoints to common targets or pathways, responsible for executing rhabdomyolysis. A drop in myoplasmic ATP paralleled with sustained elevations in cytosolic Ca²⁺ concentration represents a common signature of rhabdomyolysis. Interestingly, cardiac tissue is hardly affected or only secondary, as a consequence of imbalance in electrolytes or acid-base equilibrium. This dogma is now impaired by compounds, which show up with combined toxicity in heart and skeletal muscle. In this review, cases of rhabdomyolysis with novel recently approved drugs will be explored for new target mechanisms in the light of previously described pathomechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.